{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:07:32Z","timestamp":1793236052647,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>There is a lack of consensus in treating infants with extended-spectrum beta-lactamase producing Enterobacteriaceae (ESBL-E) urinary tract infection (UTI) who demonstrate good clinical response to initial antibiotics within 48\u00a0h.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted an international survey among paediatric nephrologists and fellows in training using a web-based questionnaire.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 232 centres across 77 countries participated in the survey. Second- or third-generation cephalosporins were the initial antibiotic of choice upon presentation in 63.8% of the centres. If the ESBL-E isolated from urine culture demonstrated in vitro susceptibility, 81.0% of respondents would continue the initial oral antibiotics. In contrast, there was considerable practice variation in the presence of in vitro resistance to the initial oral antibiotic. 19.0% would switch to a carbapenem group antibiotic, while 49.6% would change to a non-carbapenem antibiotic according to the sensitivity profiles. 22.8% would continue initial antibiotics based on satisfactory clinical response. The remaining 8.6% would choose other options. Similar emphasis on in vitro susceptibility result for the treatment was observed among centres who treated patients with intravenous antibiotics at UTI presentation. In the presence of a UTI with an ESBL-E, 50.0% centres would perform additional radiological investigations, and 61.2% would offer antibiotic prophylaxis to prevent further UTIs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>There are significant variations in the management of UTI caused by ESBL-E bacteria between centres. In vitro susceptibility to the antibiotics remains an important management consideration. Antibiotics from the non-carbapenem groups seem to be the preferred option. Further studies are required to identify the optimal treatment regimen in this patient population.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1007\/s00467-025-06700-w","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T23:49:27Z","timestamp":1738712967000},"page":"2253-2266","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Controversies in treating febrile infantile urinary tract infection caused by extended-spectrum beta-lactamase producing Enterobacteriaceae: an international multi-centre survey"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7265-9798","authenticated-orcid":false,"given":"Sze Wa","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell","family":"Tullus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-6005","authenticated-orcid":false,"given":"Yu Hin Eugene","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"6700_CR1","doi-asserted-by":"publisher","first-page":"19460","DOI":"10.1038\/s41598-020-76520-5","volume":"10","author":"I-C Kuo","year":"2020","unstructured":"Kuo I-C, Lee J-J, Hwang D-Y, Lim L-M, Lin HY-H, Hwang S-J, Chen H-C, Hung C-C (2020) Pyuria, urinary tract infection and renal outcome in patients with chronic kidney disease stage 3\u20135. Sci Rep 10:19460. https:\/\/doi.org\/10.1038\/s41598-020-76520-5","journal-title":"Sci Rep"},{"key":"6700_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/1872213X13666181228154940","volume":"13","author":"AKC Leung","year":"2019","unstructured":"Leung AKC, Wong AHC, Leung AAM, Hon KL (2019) Urinary tract infection in children. Recent Pat Inflamm Allergy Drug Discov 13:2\u201318. https:\/\/doi.org\/10.2174\/1872213X13666181228154940","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"key":"6700_CR3","doi-asserted-by":"publisher","unstructured":"(1999) Practice parameter: the diagnosis, treatment, and evaluation of the initial urinary tract infection in febrile infants and young children. American Academy of Pediatrics. Committee on Quality Improvement. Subcommittee on Urinary Tract Infection. Pediatrics 103:843\u2013852. https:\/\/doi.org\/10.1542\/peds.103.4.843","DOI":"10.1542\/peds.103.4.843"},{"key":"6700_CR4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1542\/peds.104.1.79","volume":"104","author":"A Hoberman","year":"1999","unstructured":"Hoberman A, Wald ER, Hickey RW, Baskin M, Charron M, Majd M, Kearney DH, Reynolds EA, Ruley J, Janosky JE (1999) Oral versus initial intravenous therapy for urinary tract infections in young febrile children. Pediatrics 104:79\u201386. https:\/\/doi.org\/10.1542\/peds.104.1.79","journal-title":"Pediatrics"},{"key":"6700_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1093\/pch\/15.3.150","volume":"15","author":"J Hom","year":"2010","unstructured":"Hom J (2010) Are oral antibiotics equivalent to intravenous antibiotics for the initial management of pyelonephritis in children? Paediatr Child Health 15:150\u2013152. https:\/\/doi.org\/10.1093\/pch\/15.3.150","journal-title":"Paediatr Child Health"},{"key":"6700_CR6","doi-asserted-by":"publisher","unstructured":"Hodson EM, Willis NS, Craig JC (2007) Antibiotics for acute pyelonephritis in children. Cochrane Database Syst Rev (4):CD003772. https:\/\/doi.org\/10.1002\/14651858.CD003772.pub3","DOI":"10.1002\/14651858.CD003772.pub3"},{"key":"6700_CR7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jpurol.2016.08.026","volume":"13","author":"J Nordenstr\u00f6m","year":"2016","unstructured":"Nordenstr\u00f6m J, Holmdahl G, Brandstr\u00f6m P, Sixt R, Stokland E, Sill\u00e9n U, Sj\u00f6str\u00f6m S (2016) The Swedish infant high-grade reflux trial: study presentation and vesicoureteral reflux outcome. J Pediatr Urol 13:130\u2013138. https:\/\/doi.org\/10.1016\/j.jpurol.2016.08.026","journal-title":"J Pediatr Urol"},{"key":"6700_CR8","doi-asserted-by":"publisher","first-page":"e20163026","DOI":"10.1542\/peds.2016-3026","volume":"138","author":"Subcommittee On Urinary Tract Infection","year":"2016","unstructured":"Subcommittee On Urinary Tract Infection (2016) Reaffirmation of AAP clinical practice guideline: the diagnosis and management of the initial urinary tract infection in febrile infants and young children 2\u201324 months of age. Pediatrics 138:e20163026\u2013e20163026. https:\/\/doi.org\/10.1542\/peds.2016-3026","journal-title":"Pediatrics"},{"key":"6700_CR9","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/apa.14988","volume":"109","author":"A Ammenti","year":"2020","unstructured":"Ammenti A, Alberici I, Brugnara M et al (2020) Updated Italian recommendations for the diagnosis, treatment and follow-up of the first febrile urinary tract infection in young children. Acta Paediatr 109:236\u2013247. https:\/\/doi.org\/10.1111\/apa.14988","journal-title":"Acta Paediatr"},{"key":"6700_CR10","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/j.1469-0691.2007.01850.x","volume":"14","author":"R Canton","year":"2008","unstructured":"Canton R, Novais A, Valverde A, Machado E, Peixe L, Baquero F, Coque TM (2008) Prevalence and spread of extended-spectrum b-lactamase-producing Enterobacteriaceae in Europe. Clin Microbiol Infect 14:144\u2013153. https:\/\/doi.org\/10.1111\/j.1469-0691.2007.01850.x","journal-title":"Clin Microbiol Infect"},{"key":"6700_CR11","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.jinf.2016.07.014","volume":"73","author":"ME Flokas","year":"2016","unstructured":"Flokas ME, Detsis M, Alevizakos M, Mylonakis E (2016) Prevalence of ESBL-producing Enterobacteriaceae in paediatric urinary tract infections: a systematic review and meta-analysis. J Infect 73:547\u2013557. https:\/\/doi.org\/10.1016\/j.jinf.2016.07.014","journal-title":"J Infect"},{"key":"6700_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.cmi.2020.10.016","volume":"27","author":"ZR Palacios-Baena","year":"2021","unstructured":"Palacios-Baena ZR, Giannella M, Manissero D, Rodr\u00edguez-Ba\u00f1o J, Viale P, Lopes S, Wilson K, McCool R, Longshaw C (2021) Risk factors for carbapenem-resistant Gram-negative bacterial infections: a systematic review. Clin Microbiol Infect 27:228\u2013235. https:\/\/doi.org\/10.1016\/j.cmi.2020.10.016","journal-title":"Clin Microbiol Infect"},{"key":"6700_CR13","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1128\/JCM.39.6.2206-2212.2001","volume":"39","author":"DL Paterson","year":"2001","unstructured":"Paterson DL, Ko W-C, Von Gottberg A, Casellas JM, Mulazimoglu L, Klugman KP, Bonomo RA, Rice LB, McCormack JG, Yu VL (2001) Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum \u03b2-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 39:2206\u20132212. https:\/\/doi.org\/10.1128\/JCM.39.6.2206-2212.2001","journal-title":"J Clin Microbiol"},{"key":"6700_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/420816","volume":"39","author":"DL Paterson","year":"2004","unstructured":"Paterson DL, Ko W-C, Gottberg AV, Mohapatra S, Casellas JM, Goossens H, Mulazimoglu L, Trenholme G, Klugman KP, Bonomo RA, Rice LB, Wagener MM, McCormack JG, Yu VL (2004) Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum \u03b2-lactamases. Clin Infect Dis 39:31\u201337. https:\/\/doi.org\/10.1086\/420816","journal-title":"Clin Infect Dis"},{"key":"6700_CR15","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1093\/jac\/dku215","volume":"69","author":"SH Park","year":"2014","unstructured":"Park SH, Choi S-M, Chang YK, Lee D-G, Cho S-Y, Lee H-J, Choi J-H, Yoo J-H (2014) The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum-lactamase-producing Escherichia coli. J Antimicrob Chemother 69:2848\u20132856. https:\/\/doi.org\/10.1093\/jac\/dku215","journal-title":"J Antimicrob Chemother"},{"key":"6700_CR16","doi-asserted-by":"publisher","unstructured":"Madhi F, Jung C, Timsit S, Levy C, Biscardi S, Lorrot M, Grimprel E, Hees L, Craiu I, Galerne A, Dubos F, Cixous E, Hentgen V, B\u00e9chet S, on behalf of the Urinary-tract Infection due to Extended-Spectrum Beta-lactamase\u2013producing Enterobacteriaceae in Children Group, Bonacorsi S, Cohen R (2018) Febrile urinary-tract infection due to extended-spectrum beta-lactamase\u2013producing Enterobacteriaceae in children: a French prospective multicenter study. PLoS One 13:e0190910. https:\/\/doi.org\/10.1371\/journal.pone.0190910","DOI":"10.1371\/journal.pone.0190910"},{"key":"6700_CR17","doi-asserted-by":"publisher","first-page":"e13792","DOI":"10.5812\/jjm.13792","volume":"8","author":"A Beytur","year":"2014","unstructured":"Beytur A, Yakupogullari Y, Oguz F, Otlu B, Kaysadu H (2014) Oral amoxicillin-clavulanic acid treatment in urinary tract infections caused by extended-spectrum beta-lactamase\u2013producing organisms. Jundishapur J Microbiol 8:e13792. https:\/\/doi.org\/10.5812\/jjm.13792","journal-title":"Jundishapur J Microbiol"},{"key":"6700_CR18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1371\/journal.pone.0190910","volume":"25","author":"E Kim","year":"2021","unstructured":"Kim E, Ahn YH, Lee JW, Park E (2021) Clinical outcomes of non-carbapenem treatment for urinary tract infections caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli. Child Kidney Dis 25:22\u201328.\u00a0https:\/\/doi.org\/10.3339\/jkspn.2021.25.1.22","journal-title":"Child Kidney Dis"},{"key":"6700_CR19","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1007\/s00467-019-04298-4","volume":"34","author":"HS Hyun","year":"2019","unstructured":"Hyun HS, Kim JH, Cho MH, Park E, Ha I-S, Cheong HI, Kang HG (2019) Low relapse rate of urinary tract infections from extended-spectrum beta-lactamase-producing bacteria in young children. Pediatr Nephrol 34:2399\u20132407. https:\/\/doi.org\/10.1007\/s00467-019-04298-4","journal-title":"Pediatr Nephrol"},{"key":"6700_CR20","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2298\/SARH1206321P","volume":"140","author":"A Peco-Antic","year":"2012","unstructured":"Peco-Antic A, Paripovic D, Buljugic S, Spasojevic-Dimitrijeva B, Cvetkovic M, Laban-Nestorovic S, Milosevski-Lomic G (2012) In vivo susceptibility of ESBL producing Escherichia coli to ceftriaxone in children with acute pyelonephritis. Srp Arh Celok Lek 140:321\u2013325. https:\/\/doi.org\/10.2298\/SARH1206321P","journal-title":"Srp Arh Celok Lek"},{"key":"6700_CR21","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1681\/ASN.2021111472","volume":"33","author":"EY Chan","year":"2022","unstructured":"Chan EY, Yu ELM, Angeletti A et al (2022) Long-term efficacy and safety of repeated rituximab to maintain remission in idiopathic childhood nephrotic syndrome: an international study. J Am Soc Nephrol 33:1193\u20131207. https:\/\/doi.org\/10.1681\/ASN.2021111472","journal-title":"J Am Soc Nephrol"},{"key":"6700_CR22","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.kint.2019.09.033","volume":"97","author":"EY Chan","year":"2020","unstructured":"Chan EY, Webb H, Yu E, Ghiggeri GM, Kemper MJ, Ma AL, Yamamura T, Sinha A, Bagga A, Hogan J, Dossier C, Vivarelli M, Liu ID, Kamei K, Ishikura K, Saini P, Tullus K (2020) Both the rituximab dose and maintenance immunosuppression in steroid-dependent\/frequently-relapsing nephrotic syndrome have important effects on outcomes. Kidney Int 97:393\u2013401. https:\/\/doi.org\/10.1016\/j.kint.2019.09.033","journal-title":"Kidney Int"},{"key":"6700_CR23","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.kint.2024.09.011","volume":"6","author":"EY Chan","year":"2024","unstructured":"Chan EY, Sinha A, Yu EL et al (2024) An international, multi-center study evaluated rituximab therapy in childhood steroid-resistant nephrotic syndrome. Kidney Int 6:1142\u20131157. https:\/\/doi.org\/10.1016\/j.kint.2024.09.011","journal-title":"Kidney Int"},{"key":"6700_CR24","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1365-2710.2007.00836.x","volume":"32","author":"K Urb\u00e1nek","year":"2007","unstructured":"Urb\u00e1nek K, Kol\u00e1\u0159 M, Love\u010dkov\u00e1 Y, Strojil J, \u0160antav\u00e1 L (2007) Influence of third-generation cephalosporin utilization on the occurrence of ESBL-positive Klebsiella pneumoniae strains. J Clin Pharm Ther 32:403\u2013408. https:\/\/doi.org\/10.1111\/j.1365-2710.2007.00836.x","journal-title":"J Clin Pharm Ther"},{"key":"6700_CR25","doi-asserted-by":"publisher","first-page":"ofac034","DOI":"10.1093\/ofid\/ofac034","volume":"9","author":"DT Anderson","year":"2022","unstructured":"Anderson DT, Albrecht B, Jones KA, Jacob JT, Sexton ME, Wiley Z, Dube WC, Lee B, Suchindran S (2022) Efficacy of noncarbapenem \u03b2-lactams compared to carbapenems for extended-spectrum \u03b2-lactamase\u2013producing Enterobacterales urinary tract infections. Open Forum Infect Dis 9:ofac034. https:\/\/doi.org\/10.1093\/ofid\/ofac034","journal-title":"Open Forum Infect Dis"},{"key":"6700_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1177\/0018578718817933","volume":"55","author":"JB Tullos","year":"2020","unstructured":"Tullos JB, Stoudenmire LL, Pouliot JD (2020) Piperacillin-tazobactam versus carbapenems for the treatment of nonbacteremic urinary tract infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae. Hosp Pharm 55:44\u201349. https:\/\/doi.org\/10.1177\/0018578718817933","journal-title":"Hosp Pharm"},{"key":"6700_CR27","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","volume":"18","author":"DL Paterson","year":"2005","unstructured":"Paterson DL, Bonomo RA (2005) Extended-spectrum \u03b2-lactamases: a clinical update. Clin Microbiol Rev 18:657\u2013686. https:\/\/doi.org\/10.1128\/CMR.18.4.657-686.2005","journal-title":"Clin Microbiol Rev"},{"key":"6700_CR28","doi-asserted-by":"publisher","first-page":"dlab092","DOI":"10.1093\/jacamr\/dlab092","volume":"3","author":"M Castanheira","year":"2021","unstructured":"Castanheira M, Simner PJ, Bradford PA (2021) Extended-spectrum \u03b2-lactamases: an update on their characteristics, epidemiology and detection. JAC-Antimicrob Resist 3:dlab092. https:\/\/doi.org\/10.1093\/jacamr\/dlab092","journal-title":"JAC-Antimicrob Resist"},{"key":"6700_CR29","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1469-0691.2007.01858.x","volume":"14","author":"DM Livermore","year":"2008","unstructured":"Livermore DM, Hope R, Mushtaq S, Warner M (2008) Orthodox and unorthodox clavulanate combinations against extended-spectrum \u03b2-lactamase producers. Clin Microbiol Infect 14:189\u2013193. https:\/\/doi.org\/10.1111\/j.1469-0691.2007.01858.x","journal-title":"Clin Microbiol Infect"},{"key":"6700_CR30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1469-0691.2007.01849.x","volume":"14","author":"R Cant\u00f3n","year":"2008","unstructured":"Cant\u00f3n R, Morosini MI, Martin O, De La Maza S, De La Pedrosa EGG (2008) IRT and CMT \u03b2-lactamases and inhibitor resistance. Clin Microbiol Infect 14:53\u201362. https:\/\/doi.org\/10.1111\/j.1469-0691.2007.01849.x","journal-title":"Clin Microbiol Infect"},{"key":"6700_CR31","doi-asserted-by":"publisher","first-page":"156","DOI":"10.5863\/1551-6776-19.3.156","volume":"19","author":"J Curello","year":"2014","unstructured":"Curello J, MacDougall C (2014) Beyond susceptible and resistant, part II: treatment of infections due to Gram-negative organisms producing extended-spectrum \u03b2-lactamases. J Pediatr Pharmacol Ther 19:156\u2013164. https:\/\/doi.org\/10.5863\/1551-6776-19.3.156","journal-title":"J Pediatr Pharmacol Ther"},{"key":"6700_CR32","doi-asserted-by":"publisher","unstructured":"(1998) Methods for the determination of susceptibility of bacteria to antimicrobial agents. Terminology. Clin Microbiol Infect 4:291\u2013296. https:\/\/doi.org\/10.1111\/j.1469-0691.1998.tb00061.x","DOI":"10.1111\/j.1469-0691.1998.tb00061.x"},{"key":"6700_CR33","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1469-0691.2005.01265.x","volume":"11","author":"D Andes","year":"2005","unstructured":"Andes D, Craig WA (2005) Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations. Clin Microbiol Infect 11:10\u201317. https:\/\/doi.org\/10.1111\/j.1469-0691.2005.01265.x","journal-title":"Clin Microbiol Infect"},{"key":"6700_CR34","first-page":"17","volume":"77","author":"IH Patel","year":"1984","unstructured":"Patel IH, Kaplan SA (1984) Pharmacokinetic profile of ceftriaxone in man. Am J Med 77:17\u201325","journal-title":"Am J Med"},{"key":"6700_CR35","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s10096-016-2577-0","volume":"35","author":"BA Cunha","year":"2016","unstructured":"Cunha BA (2016) An infectious disease and pharmacokinetic perspective on oral antibiotic treatment of uncomplicated urinary tract infections due to multidrug-resistant Gram-negative uropathogens: the importance of urinary antibiotic concentrations and urinary pH. Eur J Clin Microbiol Infect Dis 35:521\u2013526. https:\/\/doi.org\/10.1007\/s10096-016-2577-0","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"6700_CR36","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/j.1875-9114.1984.tb03333.x","volume":"4","author":"DJ Weber","year":"1984","unstructured":"Weber DJ, Tolkoff-Rubin NE, Rubin RH (1984) Amoxicillin and potassium clavulanate: an antibiotic combination. Mechanism of action, pharmacokinetics, antimicrobial spectrum, clinical efficacy and adverse effects. Pharmacotherapy 4:122\u2013136. https:\/\/doi.org\/10.1002\/j.1875-9114.1984.tb03333.x","journal-title":"Pharmacotherapy"},{"key":"6700_CR37","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1186\/s13104-018-3599-8","volume":"11","author":"DB Chastain","year":"2018","unstructured":"Chastain DB, King ST, Stover KR (2018) Rethinking urinary antibiotic breakpoints: analysis of urinary antibiotic concentrations to treat multidrug resistant organisms. BMC Res Notes 11:497. https:\/\/doi.org\/10.1186\/s13104-018-3599-8","journal-title":"BMC Res Notes"},{"key":"6700_CR38","unstructured":"Overview | Urinary tract infection in under 16s: diagnosis and management | Guidance | NICE (2022) Available at: https:\/\/www.nice.org.uk\/guidance\/ng224. Accessed December 22, 2024"},{"key":"6700_CR39","doi-asserted-by":"publisher","unstructured":"Wei Y, Yu C, Zhao T, Lin T, He D, Wu S, Wei G (2020) Etiological characteristic and risk factors of ESBL-urinary tract infections: a nomogram had been built and Urologist should act in time. ResearchSquare. https:\/\/doi.org\/10.21203\/rs.3.rs-31324\/v1","DOI":"10.21203\/rs.3.rs-31324\/v1"},{"key":"6700_CR40","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1093\/jac\/dkl035","volume":"57","author":"E Calbo","year":"2006","unstructured":"Calbo E, Roman\u00ed V, Xercavins M, G\u00f3mez L, Vidal CG, Quintana S, Vila J, Garau J (2006) Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum \u03b2-lactamases. J Antimicrob Chemother 57:780\u2013783. https:\/\/doi.org\/10.1093\/jac\/dkl035","journal-title":"J Antimicrob Chemother"},{"key":"6700_CR41","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.eimce.2017.03.008","volume":"35","author":"RH Marco","year":"2017","unstructured":"Marco RH, Olmos EG, Bret\u00f3n-Mart\u00ednez JR, P\u00e9rez LG, S\u00e1nchez BC, Fujkova J, Campos MS, Coito JMN (2017) Community-acquired febrile urinary tract infection caused by extended-spectrum beta-lactamase-producing bacteria in hospitalised infants. Enferm Infecc Microbiol Clin 35:287\u2013292. https:\/\/doi.org\/10.1016\/j.eimce.2017.03.008","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"6700_CR42","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1017\/S0950268820003015","volume":"149","author":"P Vachvanichsanong","year":"2021","unstructured":"Vachvanichsanong P, McNeil EB, Dissaneewate P (2021) Extended-spectrum beta-lactamase Escherichia coli and Klebsiella pneumoniae urinary tract infections. Epidemiol Infect 149:e12. https:\/\/doi.org\/10.1017\/S0950268820003015","journal-title":"Epidemiol Infect"},{"key":"6700_CR43","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s00467-022-05443-2","volume":"37","author":"EY Chan","year":"2022","unstructured":"Chan EY (2022) Community-acquired urinary tract infections caused by ESBL-producing Enterobacteriaceae in infants less than 2 years of age. Pediatr Nephrol 37:1167\u20131168. https:\/\/doi.org\/10.1007\/s00467-022-05443-2","journal-title":"Pediatr Nephrol"},{"key":"6700_CR44","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1056\/NEJMoa1401811","volume":"370","author":"The RIVUR Trial Investigators","year":"2014","unstructured":"The RIVUR Trial Investigators (2014) Antimicrobial prophylaxis for children with vesicoureteral reflux. N Engl J Med 370:2367\u20132376. https:\/\/doi.org\/10.1056\/NEJMoa1401811","journal-title":"N Engl J Med"},{"key":"6700_CR45","doi-asserted-by":"publisher","unstructured":"Williams G, Craig JC (2011) Long-term antibiotics for preventing recurrent urinary tract infection in children. Cochrane Database Syst Rev (4):CD001534. https:\/\/doi.org\/10.1002\/14651858.CD001534.pub3","DOI":"10.1002\/14651858.CD001534.pub3"},{"key":"6700_CR46","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00467-014-2943-z","volume":"30","author":"P Hari","year":"2015","unstructured":"Hari P, Hari S, Sinha A, Kumar R, Kapil A, Pandey RM, Bagga A (2015) Antibiotic prophylaxis in the management of vesicoureteric reflux: a randomized double-blind placebo-controlled trial. Pediatr Nephrol 30:479\u2013486. https:\/\/doi.org\/10.1007\/s00467-014-2943-z","journal-title":"Pediatr Nephrol"},{"key":"6700_CR47","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.juro.2010.01.060","volume":"184","author":"P Brandstr\u00f6m","year":"2010","unstructured":"Brandstr\u00f6m P, Nev\u00e9us T, Sixt R, Stokland E, Jodal U, Hansson S (2010) The Swedish reflux trial in children: IV. Renal damage J Urol 184:292\u2013297. https:\/\/doi.org\/10.1016\/j.juro.2010.01.060","journal-title":"Renal damage J Urol"},{"key":"6700_CR48","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa2300161","volume":"389","author":"W Morello","year":"2023","unstructured":"Morello W, Baskin E, Jankauskiene A et al (2023) Antibiotic prophylaxis in infants with grade III, IV, or V vesicoureteral reflux. N Engl J Med 389:987\u2013997. https:\/\/doi.org\/10.1056\/NEJMoa2300161","journal-title":"N Engl J Med"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06700-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-025-06700-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06700-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T09:17:52Z","timestamp":1748337472000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-025-06700-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["6700"],"URL":"https:\/\/doi.org\/10.1007\/s00467-025-06700-w","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"assertion":[{"value":"23 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}